NOTCH3 and chronic myelogenous leukemia, BCR-ABL1 positive: It was also found that mutations in NOTCH3 and RELN were present only in subjects who did not achieve MMR at 12 months, indicating that CML-CP patients with these two mutations might have a poor response to TKI therapy.